Treatment options for BCG failures

World Journal of Urology

Volumn 24, Issue 5, 2006, Pages 481-487

  O'Donnell, Michael A ^a   Boehle, Andreas ^b  

^a UNIVERSITY OF IOWA   (United States)

^b HELIOS AGNES KARLL HOSPITAL   (Germany)

Author keywords

BCG; Bladder neoplasms; Outcome assessment

Indexed keywords

ANTINEOPLASTIC AGENT; BCG CONNAUGHT; BCG VACCINE; INTERFERON;

ARTICLE; BLADDER TUMOR; CYSTECTOMY; DRUG COMBINATION; DRUG RESISTANCE; HUMAN; MICROBIOLOGY; RECURRENT DISEASE;

ANTINEOPLASTIC AGENTS; BCG VACCINE; CYSTECTOMY; DRUG RESISTANCE, NEOPLASM; DRUG THERAPY, COMBINATION; HUMANS; INTERFERONS; RECURRENCE; URINARY BLADDER NEOPLASMS;

EID: 33751219575     PISSN: 07244983     EISSN: 14338726     Source Type: Journal    
DOI: 10.1007/s00345-006-0112-0     Document Type: Article

References (60)

1. Sylvester RJ, van der Meijden AP, Witjes JA, Kurth K (2005) Bacillus Calmette-Guerin versus chemotherapy for the intravesical treatment of patients with carcinoma in situ of the bladder: A meta-analysis of the published results of randomized clinical trials. J Urol 174:86-91
2. Herr HW, Dalbagni G (2003) Defining bacillus Calmette-Guerin refractory superficial bladder tumors. J Urol 169:1706-1708
3. Klein EA, Rogatko A, Herr HW (1992) Management of local bacillus Calmette-Guerin failures in superficial bladder cancer. J Urol 147:601-605
4. Glashan RW (1990) A randomized controlled study of intravesical alpha-2b-interferon in carcinoma in situ of the bladder. J Urol 144:658-661
5. Sarosdy MF, Manyak MJ, Sagalowsky AI, et al (1998) Oral bropirimine immunotherapy of bladder carcinoma in situ after prior intravesical bacille Calmette-Guerin. Urology 51:226-231
6. Dalbagni G, Russo P, Sheinfeld J, et al (2002) Phase I trial of intravesical gemcitabine in bacillus Calmette-Guerin-refractory transitional-cell carcinoma of the bladder. J Clin Oncol 20:3193-3198
7. O'Donnell MA, Krohn J, DeWolf WC (2001) Salvage intravesical therapy with interferon-alpha 2b plus low dose bacillus Calmette-Guerin is effective in patients with superficial bladder cancer in whom bacillus Calmette-Guerin alone previously failed. J Urol 166:1300-1304
8. Luciani LG, Neulander E, Murphy WM, et al (2001) Risk of continued intravesical therapy and delayed cystectomy in BCG-refractory superficial bladder cancer: An investigational approach. Urology 58:376-379
9. Martinez-Pineiro JA, Martinez-Pineiro L, Solsona E, et al (2005) Has a 3-fold decreased dose of bacillus Calmette-Guerin the same efficacy against recurrences and progression of T1G3 and Tis bladder tumors than the standard dose? Results of a prospective randomized trial. J Urol 174:1242-1247
10. Bassi P, Spinadin R, Carando R, et al (2000) Modified induction course: a solution to side-effects? Eur Urol 37(Suppl 1):31-32
11. Andius P, Fehrling M, Holmang S (2005) Intravesical bacillus Calmette-Guerin therapy: Experience with a reduced dwell-time in patients with pronounced side-effects. BJU Int 96:1290-1293
12. Rischmann P, Colombel M, Chopin DK, et al (2006) Prophylactic ofloxacin to improve tolerance of BCG intravesical instillations: A randomised prospective, double blind, placebo-controlled, multicentre study in patients with mid to high risk superficial bladder tumors. J Urol 175(Suppl 4):269 (abstract 835)
13. Dovedi SJ, Kirby JA, Atkins H, et al (2005) Cyclooxygenase-2 inhibition: a potential mechanism for increasing the efficacy of bacillus Calmette-Guerin immunotherapy for bladder cancer. J Urol 174:332-337
14. Sylvester RJ, van der Meijden AP, Oosterlinck W, et al (2003) The side effects of Bacillus Calmette-Guerin in the treatment of Ta T1 bladder cancer do not predict its efficacy: Results from a European Organisation for Research and Treatment of Cancer Genito-Urinary Group Phase III Trial. Eur Urol 44:423-428
15. Merz VW, Marth D, Kraft R, et al (1995) Analysis of early failures after intravesical instillation therapy with bacille Calmette-Guerin for carcinoma in situ of the bladder. Br J Urol 75:180-184
16. Bretton PR, Herr HW, Kimmel M, et al (1990) The response of patients with superficial bladder cancer to a second course of intravesical bacillus Calmette-Guerin. J Urol 143:710-713
17. Nadler RB, Catalona WJ, Hudson M, et al (1994) Durability of the tumor-free response for intravesical bacillus Calmette-Guerin therapy. J Urol 152:367-373
18. Yamada Y, Hara I, Kumano M, et al (2005) Is second course intravesical Bacillus Calmette-Guerin therapy for recurrent carcinoma in situ of the bladder useful? Hinyokika Kiyo 51:539-543
19. Ovesen H, Poulsen AL, Steven K (1993) Intravesical Bacillus Calmette-Guerin with the Danish strain for treatment of carcinoma in situ of the bladder. Br J Urol 72:744-748
20. Brake M, Loertzer H, Horsch R, et al (2000) Long-term results of inrravesical bacillus Calmette-Guerin therapy for stage T1 superficial bladder cancer. Urology 55:673-678
21. Pansadoro V, De Paula F (1987) Intravesical bacillus Calmette-Guerin in the treatment of superficial transitional cell carcinoma of the bladder. J Urol 138:299-301
22. Catalona WJ, Hudson MA, Gillen DP, et al (1987) Risks and benefits of repeated courses of intravesical bacillus Calmette-Guerin therapy for superficial bladder cancer. J Urol 137:220-224
23. Malmstrom PU, Wijkstrom H, Lundholm C, et al (1999) 5-year followup of a randomized prospective study comparing mitomycin C and bacillus Calmette-Guerin in patients with superficial bladder carcinoma. Swedish-Norwegian Bladder Cancer Study Group. J Urol 161:1124-1127
24. Steinberg G, Bahnson R, Brosman S, et al (2000) Efficacy and safety of valrubicin for the treatment of bacillus Calmette-Guerin refractory carcinoma in situ of the bladder. J Urol 163:761-767
25. Belldegrun AS, Franklin JR, O'Donnell MA, et al (1998) Superficial bladder cancer: The role of interferon-alpha. J Urol 159:1793-1801
26. Portillo J, Martin B, Hernandez R, et al (1997) Results at 43 months' follow-up of a double-blind, randomized, prospective clinical trial using intravesical interferon alpha-2b in the prophylaxis of stage pT1 transitional cell carcinoma of the bladder. Urology 49:187-190
27. Punnen SP, Chin JL, Jewett MA (2003) Management of bacillus Calmette-Guerin (BCG) refractory superficial bladder cancer: Results with intravesical BCG and Interferon combination therapy. Can J Urol 10:1790-1795
28. Lam JS, Benson MC, O'Donnell MA, et al (2003) Bacillus Calmette-Guerin plus interferon-alpha2B intravesical therapy maintains an extended treatment plan for superficial bladder cancer with minimal toxicity. Urol Oncol 21:354-360
29. Sawczuk IS, Munver R, Fromer DL, et al (2006) Intravesical BCG and interferon-alpha 2B therapy prior to cystectomy does not impact negatively on survival in patients with recurrent superficial bladder cancer. J Urol 175(Suppl 4):404 (abstract 1255)
30. Joudi FN, Smith BJ, O'Donnell MA, et al (2006) Final results from a national multicenter phase II trial of combination bacillus Calmette-Guérin plus interferon alpha-2B for reducing recurrence of superficial bladder cancer. Urol Oncol 24:344-348
31. Gallagher BL, Joudi FN, O'Donnell MA (2006) Response to intravesical immunotherapy in BCG naïve and BCG treated patients. J Urol 175(Suppl 4):268 (abstract 831)
32. Maymi JL, O'Donnell MA, the National BCG/Interferon Investigator Group (2005) Factors affecting response to BCG plus interferon in patients with urothelial carcinoma in situ. J Urol 173(Suppl 4):248 (abstract 918)
33. Colombo R, Da Pozzo LF, Salonia A, et al (2003) Multicentric study comparing intravesical chemotherapy alone and with local microwave hyperthermia for prophylaxis of recurrence of superficial transitional cell carcinoma. J Clin Oncol 21:4270-4276
34. Gofrit ON, Shapiro A, Pode D, et al (2004) Combined local bladder hyperthermia and intravesical chemotherapy for the treatment of high-grade superficial bladder cancer. Urology 63:466-471
35. van der Heijden AG, Kiemeney LA, Gofrit ON, et al (2004) Preliminary European results of local microwave hyperthermia and chemotherapy treatment in intermediate or high risk superficial transitional cell carcinoma of the bladder. Eur Urol 46:65-71
36. Di Stasi SM, Giannantoni A, Stephen RL, et al (2003) Intravesical electromotive mitomycin C versus passive transport mitomycin C for high risk superficial bladder cancer: A prospective randomized study. J Urol 170:777-782
37. Bouffioux C, Denis L, Oosterlinck W, et al (1992) Adjuvant chemotherapy of recurrent superficial transitional cell carcinoma: Results of a European Organization for Research on Treatment of Cancer randomized trial comparing intravesical instillation of thiotepa, doxorubicin and cisplatin. J Urol 148:297-301
38. Morabito F, Rossi R, Graziano ME, et al (2006) Multicenter study on the use of gemcitabine to prevent recurrence of multiple-recurring superficial bladder tumors following intravesical antiblastic agents and/ or BCG: Evaluation of tolerance. Arch Ital Urol Androl 78:1-4
39. Gontero P, Frea B (2006) Actual experience and future development of gemcitabine in superficial bladder cancer. Ann Oncol 17(Suppl 5):v123-v128
40. Bassi P, De Marco V, Tavolini IM, et al (2005) Pharmacokinetic study of intravesical gemcitabine in carcinoma in situ of the bladder refractory to bacillus Calmette-Guerin therapy. Urol Int 75:309-313
41. Gacci M, Bartoletti R, Cai T, et al (2006) Intravesical gemcitabine in BCG-refractory T1G3 transitional cell carcinoma of the bladder: A pilot study. Urol Int 76:106-111
42. Dalbagni G, Russo P, Bochner B, et al (2006) Phase II trial of intravesical gemcitabine in bacille Calmette-Guerin-refractory transitional cell carcinoma of the bladder. J Clin Oncol 24:2729-2734
43. McKiernan JM, Murphy AM, Goetzl M, et al (2005) Phase I trial intravesical docetaxel (Taxotere) for recurrent superficial bladder cancer. J Urol 173(Suppl 4):247 (abstract 916)
44. Masson P, Murphy AM, Goetzl MA, et al (2006) Long-term follow up of intravesical docetaxel for the treatment of superficial bladder cancer resistant to standard intravesical therapy. J Urol 175(Suppl 4):273 (abstract 846)
45. Fukui I, Sekine H, Kihara K, et al (1989) Intravesical combination chemotherapy with mitomycin C and doxorubicin for carcinoma in situ of the bladder. J Urol 141:531-534
46. Maymi JL, Saltsgaver N, O'Donnell MA (2006) Intravesical sequential gemcitabine-mitomycin chemotherapy as salvage treatment for patients with refractory superficial bladder cancer. J Urol 175(Suppl 4):271 (abstract 840)
47. Akcetin Z, Todorov J, Tuzel E, et al (2005) Radiochemotherapy after transurethral resection is an effective treatment method in T1G3 bladder cancer. Anticancer Res 25:1623-1628
48. Nseyo UO, Shumaker B, Klein EA, et al (1998) Photodynamic therapy using porfimer sodium as an alternative to cystectomy in patients with refractory transitional cell carcinoma in situ of the bladder. Bladder Photofrin Study Group. J Urol 160:39-44
49. Marti A, Jichlinski P, Lange N, et al (2003) Comparison of aminolevulinic acid and hexylester aminolevulinate induced protoporphyrin IX distribution in human bladder cancer. J Urol 170:428-432
50. Smith JA Jr, Labasky RF, Cockett AT, et al (1999) Bladder cancer clinical guidelines panel summary report on the management of nonmuscle invasive bladder cancer (stages Ta, T1, and TIS). The American Urological Association. J Urol 162:1697-1701
51. Sylvester RJ, van der Meijden A, Witjes JA, et al (2005) High-grade Ta urothelial carcinoma and carcinoma in situ of the bladder. Urology 66(6 Suppl 1):90-107
52. Nieder AM, Brausi M, Lamm D, et al (2005) Management of stage T1 tumors of the bladder: International consensus panel. Urology 66(6 Suppl 1):108-125
53. Herr HW, Badalament RA, Amato DA, et al (1989) Superficial bladder cancer treated with bacillus Calmette-Guerin: A multivariate analysis of factors affecting tumor progression. J Urol 141:22-29
54. Herr H (2000) Tumor progression and survival of patients with high grade, noninvasive papillary (TaG3) bladder tumors: 15-year outcome. J Urol 163:60-62
55. Kurth KH, Denis L, Bouffioux C, et al (1995) Factors affecting recurrence and progression in superficial bladder cancer. Eur J Cancer 31A:1840-1846
56. Huguet J, Crego M, Sabate S, et al (2005) Cystectomy in patients with high risk superficial bladder tumors who fail intravesical BCG therapy: pre-cystectomy prostate involvement as a prognostic factor. Eur Urol 48:53-59
57. Habuchi T, Marberger M, Droller MJ, et al (2005) Prognostic markers for bladder cancer: International consensus panel on bladder tumor markers. Urology 66(6 Suppl 1):64-74
58. Stein JP, Lieskovsky G, Cote R, et al (2001) Radical cystectomy in the treatment of invasive bladder cancer: Long-term results in 1,054 patients. J Clin Oncol 19:666-675
59. Joudi FN, Smith BJ, O'Donnell MA, et al (2003) Contemporary management of superficial bladder cancer in the United States: A pattern of care analysis. Urology 62:1083-1088
60. Herr WH, Sogani PC (2001) Does early cystectomy improve the survival of patients with high risk superficial bladder tumors? J Urol 166:1296-1299